SKLB06329

SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Formule: C20H25N5O2S
  • Masse moléculaire:399.51
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
100 mg

Obtenir un devis En stock

Please select quantity
Amount: USD 0.00